Introduction
============

In recent years, extended-spectrum beta-lactamase (ESBL) is well recognized worldwide as a major cause of cephalosporin resistance among *Enterobacteriaceae* ([@B1]), with *Escherichia coli* (*E. coli*) in particular being a clinically important pathogen ([@B2]). Carbapenems have become widely recognized as the primary choice for the treatment of serious infections caused by ESBL-producing *Enterobacteriaceae* ([@B3]). However, a previous report showed that β-lactam/β-lactamase inhibitors (BLBLI), including tazobactam/piperacillin (TAZ/PIPC), are clinically reliable for the treatment of serious infections caused by ESBL-producing *Enterobacteriaceae* ([@B4]). When treating an *Enterobacteriaceae* infection, the differential diagnosis to determine whether the infection is caused by ESBL or non-ESBL-producing *Enterobacteriaceae* is important in actual clinical practice. Although some comparative studies have been reported overseas concerning bacteremia caused by ESBL-producing and non-ESBL-producing *Enterobacteriaceae* ([@B5]-[@B8]), little has been reported on this in Japan ([@B9]).

The purpose of the present study was to investigate the clinical characteristics of patients with bacteremia due to ESBL-producing *E. coli* (ESBL *E. coli*) at a tertiary hospital, including the risk factors and prognosis.

Materials and Methods
=====================

The medical records of 31 patients with ESBL *E. coli* bacteremia and 98 patients with non-ESBL *E. coli* bacteremia who had been admitted to Osaka City University Hospital between January 2011 and June 2015 were retrospectively reviewed.

The age, sex, underlying disease, clinical features, patient medication records, and prognosis were evaluated. If *E. coli* had been isolated on multiple occasions within a five-year period in the same patient, only the first episode of *E. coli* bacteremia was reviewed. This study was approved by the Ethics Committee of Osaka City University, and the thesis was approved on January 4, 2016 with approval number 3311.

Definition of bacteremia
------------------------

Bacteremia was defined as one or more positive blood cultures from patients with clinical signs of infection, such as fever, shaking chills, and sweats with or without local signs and symptoms ([@B10]). The diagnosis of *E. coli* urinary tract infection (UTI) was defined when the clinical and diagnostic findings included two more of following: 1) *E. coli* proven from a specimen of urine, 2) clinical manifestations suggestive of UTI, and 3) imaging findings suggestive of pyelonephritis. Symptoms and urinary findings including dysuria, suprapubic pain, hematuria, flank pain, costovertebral-angle tenderness, nausea or vomiting, and pyuria or bacteriuria are characteristic of UTI ([@B11]). Further, the imaging findings including perinephric stranding, renal swelling, thickening of Gerota\'s fascia, and a segmental poor enhancement region are characteristic of pyelonephritis ([@B12]). The diagnosis of *E. coli* biliary tract infection was made when the clinical and diagnostic findings included three or more of the following: 1) fever and/or shaking chills or laboratory evidence of an inflammatory response, 2) jaundice or abnormal liver chemistries, 3) biliary dilation or evidence of an etiology observed on imaging, 4) *E. coli* isolated from a specimen of bile. The diagnosis of an *E. coli* intravascular device infection was made when the clinical and diagnostic findings included one or more of the following: 1) *E. coli* growth in at least one percutaneous blood culture and in a culture of the catheter tip, 2) *E. coli* growth in a blood sample drawn from a catheter hub at least 2 hours before growth of *E. coli* is detected in a blood sample obtained from a peripheral vein ([@B13]).

Assessment of the laboratory data
---------------------------------

The leukocyte count and C-reactive protein (CRP) levels were recorded within two days of the initial blood culture and yielded a positive result. The severity of illness was evaluated by the Sequential Organ Failure Assessment (SOFA) score ([@B14]) and Pitt Bacteremia Score ([@B15]). Patients were defined as having severe sepsis when the SOFA score was ≥5 ([@B16]).

Identification of bacteria
--------------------------

All *E. coli* isolates were identified by a colony morphologic analysis, gram staining, and Triple Sugar Iron Agar. Isolate identification was confirmed using the MicroScan WalkAway-96 SI (Beckman Coulter, Brea, USA). The minimum inhibitory concentrations (MICs) were also determined using the MicroScan WalkAway-96 SI. The results of the period from January 2011 to June 2013 were interpreted in accordance with the 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints ([@B17]), and the results of the period from July 2013 to June 2015 were interpreted in accordance with the 2011 CLSI breakpoints ([@B18]). The production of ESBL was screened by measuring the MICs of cefotaxime, ceftazidime, and aztreonam.

Confirmational testing was performed using an Ambler class C & ESBL Identification Set (Kanto Chemical, Tokyo, Japan). All plates were incubated at 35°C for 24 hours.

Antimicrobial treatment
-----------------------

The specific design of the initial antimicrobial treatment regimen was the responsibility of the attending physician. Antimicrobial treatment administered within five days after bacteremia onset was defined as empirical therapy and that administered afterward as definitive therapy ([@B19]). When clinicians administered the definitive therapy, they checked that the causative isolate was *in vitro*-susceptible to the prescribed drug according to the susceptibility criteria of CLSI.

Statistical analysis
--------------------

The patient characteristics and outcomes were compared between the ESBL *E. coli* bacteremia patients and non-ESBL *E. coli* bacteremia patients. The Fisher\'s exact test was used for univariate comparison of categorical data. Variables with a p value \<0.20 in the univariate analyses were considered for inclusion in forward stepwise multivariate logistic regressions using SPSS 22.0 (IBM SPSS Statistics) to determine risk factors of this ESBL *E. coli* infection. A p value \<0.05 indicated the presence of a statistically significant difference.

Results
=======

Clinical characteristics and laboratory findings
------------------------------------------------

The isolation frequency of ESBL *E. coli* and non-ESBL *E. coli* from 2011 to 2015 are summarized in [Fig. 1](#g001){ref-type="fig"}. The clinical characteristics and laboratory findings of the 31 patients with ESBL *E. coli* bacteremia and 98 patients with non-ESBL *E. coli* bacteremia are summarized in [Table 1](#t001){ref-type="table"}. The 31 patients with ESBL *E. coli* bacteremia consisted of 12 males and 19 females with a mean age of 62.5 years. In addition, the 98 patients with non-ESBL *E. coli* bacteremia were composed of 46 males and 52 females with a mean age of 67.6 years. Of the 31 patients with ESBL *E. coli* bacteremia, 19 (61.3%) had malignancy, 13 (41.9%) had received immunosuppressive drugs or corticosteroids, and 13 (41.9%) were treated with quinolones 60 days prior to isolation. On the other hand, of the 98 patients with non-ESBL *E. coli* bacteremia, 46 (46.9%) had malignancy, 24 (24.5%) had received immunosuppressive drugs or corticosteroids, and 17 (17.3%) were treated with quinolones 60 days prior to isolation. The patients\' overseas travel history was unclear. The mean SOFA scores for patients with ESBL and non-ESBL *E. coli* bacteremia were 3.6 and 3.8, respectively. Urinary tract infection was the presumed source of ESBL *E. coli* bacteremia in 14 patients (45.2%) and non-ESBL *E. coli* bacteremia in 47 patients (48.0%).

![Isolation frequency of ESBL-producing and non-ESBL-producing*E. coli* at Osaka City University from 2011 to 2015.*E. coli*:*Escherichia coli*, ESBL: extended-spectrum beta-lactamase](1349-7235-56-1807-g001){#g001}

###### 

Clinical Characteristics and Laboratory Findings of ESBL *E. Coli* and Non-ESBL *E. Coli* bacteremia.

  Variables                                                     ESBL *E.coli* (n=31)   non-ESBL *E.coli* (n=98)
  ------------------------------------------------------------- ---------------------- --------------------------
  Sex (male/female)                                             12/19                  46/52
  Mean age (years)                                              62.5±18.9              67.6±13.9
  Underlying disease                                                                   
  Malignancy                                                    19 (61.3%)             46 (46.9%)
  Immunosuppressive drug or corticosteroid use                  13 (41.9%)             24 (24.5%)
  Diabetes mellitus                                             7 (22.6%)              28 (28.6%)
  Cardiovascular disease                                        5 (16.1%)              16 (16.3%)
  Autoimmune disease                                            1 (3.2%)               11 (11.2%)
  Respiratory disease                                           4 (12.9%)              6 (6.1%)
  Digestive disease                                             3 (9.7%)               11 (11.2%)
  Endocrine disease                                             3 (9.7%)               11 (11.2%)
  Chronic renal failure                                         3 (9.7%)               10 (10.2%)
  Central nervous system disease                                3 (9.7%)               7 (7.1%)
  Others                                                        4 (12.9%)              12 (12.2%)
  Leukocyte count (/μL)                                         9,609.7±6,786.7        11,518.4±9,855.0
  CRP (mg/dL)                                                   10.6±8.2               11.2±9.1
  SOFA score                                                    3.6±2.6                3.8±4.0
  Pitt Bacteremia Score                                         1.45±1.74              1.62±2.41
  Use of antibiotics prior to isolation                         25 (80.6%)             45 (45.9%)
  Quinolones                                                    13 (41.9%)             17 (17.3%)
  Third-generation cephalosporins                               8 (22.5%)              14 (14.3%)
  Anti-MRSA agents                                              8 (22.5%)              11 (11.2%)
  Carbapenems                                                   6 (19.4%)              9 (9.2%)
  Fourth-generation cephalosporins                              6 (19.4%)              7 (7.1%)
  Second-generation cephalosporins                              5 (16.1%)              6 (6.1%)
  None                                                          6 (19.4%)              53 (54.1%)
  Others                                                        12 (38.7%)             19 (19.4%)
  Nosocomial infection                                          24 (77.4%)             55 (56.1%)
  Hospitalization within 90 days                                15 (48.4%)             39 (39.8%)
  Two or more of the number of hospitalization within 90 days   0 (0%)                 11 (11.2%)
  Urinary catheter                                              10 (32.3%)             15 (15.3%)
  Infection site                                                                       
  Urinary tract                                                 14 (45.2%)             47 (48%)
  Biliary tract                                                 3 (9.7%)               14 (14.3%)
  Intravascular device                                          2 (6.5%)               3 (3.0%)
  Others                                                        2 (6.5%)               4 (4.1%)
  Unknown                                                       10 (32.3%)             30 (30.6%)
  Polymicrobial infection                                       1 (3.2%)               9 (9.2%)
  Confirmation of blood culture-negative conversion             12 (38.7%)             31 (31.6%)
  Mortality^a^                                                  3 (9.7%)               9 (9.2%)

^a^Both *E. coli* infection-related and otherwise

CRP: C-reactive protein, *E. coli*: *Escherichia coli*, ESBL: extended-spectrum beta-lactamase, MRSA: methicillin-resistant *Staphylococcus aureus*, SOFA: sequential organ failure assessment

Antimicrobial susceptibility
----------------------------

Various antimicrobial susceptibility rate data against ESBL and non-ESBL *E. coli* are shown in [Fig. 2](#g002){ref-type="fig"}. Notably, the susceptibility rates of levofloxacin, gentamicin, and sulfamethoxazole/trimethoprim (SMX/TMP) against ESBL *E. coli* were significantly lower than those of non-ESBL *E. coli* (12.9% vs 78.6%, 58.1% vs 96.0%, 48.4% vs 82.7%, p\<0.001, respectively).

![Various antimicrobial susceptibility rate data against ESBL-producing and non-ESBL-producing*E. coli*. AMK: amikacin, AZT: aztreonam, CAZ: ceftazidime, CMZ: cefmetazole, CTX: cefotaxime,*E. coli*:*Escherichia coli*, ESBL: extended-spectrum beta-lactamase, FOM: fosfomycin, GEM: gentamicin, IPM: imipenem, LVFX: levofloxacin, MEPM: meropenem, MINO: minocycline, ST: sulfamethoxazole/trimethoprim, TAZ/PIPC: tazobactam/piperacillin](1349-7235-56-1807-g002){#g002}

Treatment
---------

The empirical and definitive therapies against ESBL *E. coli* bacteremia and non-ESBL *E. coli* bacteremia are summarized in [Table 2](#t002){ref-type="table"}. The utilization rates of carbapenems against ESBL or non-ESBL *E. coli* bacteremia as both an empirical and definitive therapy were significantly higher than for other antimicrobial agents. Eighteen patients (58.1%) received carbapenems or TAZ/PIPC, or cefmetazole (CMZ) as appropriate empirical therapy ([@B20]) among those in the ESBL *E. coli* bacteremia group. Among the patients in the non-ESBL *E. coli* bacteremia group, the de-escalation rate was 26.7%.

###### 

Empirical and Definitive Therapy against ESBL *E. Coli* and Non-ESBL *E. Coli* bacteremia.

  Variables                          Empirical therapy   Definitive therapy                                      
  ---------------------------------- ------------------- -------------------- ---- --------- ---- --------- ---- ---------
  Carbapenems                        11                  (35.5%)              40   (40.8%)   17   (56.7%)   26   (28.2%)
  Tazobactam/Piperacillin            4                   (12.9%)              14   (14.3%)   5    (16.7%)   9    (9.8%)
  Fourth-generation cephalosporins   3                   (9.7%)               10   (10.2%)   0    (0%)      5    (5.4%)
  Third-generation cephalosporins    6                   (19.3%)              14   (14.3%)   2    (6.7%)    22   (23.9%)
  Cefmetazole                        3                   (9.7%)               6    (6.1%)    5    (16.7%)   5    (5.4%)
  Quinolones                         0                   (0%)                 4    (4.1%)    0    (0%)      9    (9.8%)
  Others                             3                   (9.7%)               5    (5.1%)    1    (3.2%)    10   (11.0%)
  None                               1                   (3.2%)               5    (5.1%)    0    (0%)      6    (6.5%)

Antimicrobial combination against ESBL *E. coli* bacteremia was not present in all cases.

^a^One patient died before definitive therapy.

^b^Four patients died and two patients was transferred to a different hospital before definitive therapy.

*E. coli*: *Escherichia coli*, ESBL: extended-spectrum beta-lactamase

Risk factors associated with ESBL E. coli bacteremia
----------------------------------------------------

The findings of a univariate analysis of risk factors associated with ESBL *E. coli* bacteremia are shown in [Table 3](#t003){ref-type="table"}. The male-to-female ratio, mean age, underlying disease, leukocyte count (≥12,000 /μL), CRP level (≥10 mg/dL), and SOFA score (≥5) did not differ between the patients in the ESBL *E. coli* bacteremia group and the non-ESBL *E. coli* bacteremia group. However, the use of quinolones 60 days prior to isolation was more frequent in the patients in the ESBL *E. coli* bacteremia group (p=0.007). Furthermore, nosocomial infection was more frequently observed (p=0.04). The mortality did not differ between the patients in the two groups. The independent predictors associated with ESBL *E. coli* bacteremia according to a multivariate analysis were the use of immunosuppressive drugs or corticosteroids (p=0.048) and quinolones (p=0.005) prior to isolation ([Table 4](#t004){ref-type="table"}).

###### 

Univariate Analysis of Risk Factors Associated with ESBL *E. Coli* bacteremia.

  Variables                                      OR (95% CI)   p value^a^     
  ---------------------------------------------- ------------- -------------- -------
  Female sex                                     1.40          (0.57-3.52)    0.54
  Age ≥ 70 years                                 0.53          (0.21-1.31)    0.15
  Underlying disease                                                          
  Malignancy                                     1.78          (0.73-4.50)    0.22
  Immunosuppressive drug or corticosteroid use   2.21          (0.86-5.62)    0.07
  Diabetes mellitus                              0.73          (0.24-2.01)    0.65
  Cardiovascular disease                         0.99          (0.26-3.18)    1.00
  Autoimmune disease                             0.27          (0.006-1.97)   0.29
  Respiratory disease                            2.25          (0.44-10.33)   0.25
  Digestive disease                              0.85          (0.14-3.53)    1.00
  Endocrine disease                              0.85          (0.14-3.53)    1.00
  Chronic renal failure                          0.94          (0.16-4.02)    1.00
  Central nervous system disease                 1.39          (0.22-6.60)    0.70
  Others                                         1.06          (0.23-3.89)    1.00
  Leukocyte count ≥ 12,000 (/μL)                 0.65          (0.24-1.66)    0.40
  CRP ≥ 10 (mg/dL)                               1.68          (0.68-4.13)    0.21
  SOFA score ≥ 5                                 1.25          (0.46-3.22)    0.65
  Use of antibiotics prior to isolation                                       
  Quinolones                                     3.40          (1.28-9.06)    0.007
  Third-generation cephalosporins                2.07          (0.67-6.10)    0.17
  Anti-MRSA agents                               2.73          (0.85-8.48)    0.08
  Carbapenems                                    2.35          (0.63-8.26)    0.19
  Fourth-generation cephalosporins               3.09          (0.78-11.84)   0.08
  Second-generation cephalosporins               2.92          (0.65-12.53)   0.13
  Others                                         2.60          (0.98-6.85)    0.05
  Nosocomial infection                           2.66          (0.99-8.02)    0.04
  Hospitalization within 90 days                 1.41          (0.58-3.45)    0.41
  Urinary catheter                               2.61          (0.91-7.30)    0.07
  Mortality^b^                                   1.06          (0.17-4.64)    1.00

^a^Fisher analysis.

^b^Both *E. coli* infection-related and otherwise.

CI: confidence interval, CRP: C-reactive protein, *E. coli*: *Escherichia coli*, ESBL: extended-spectrum beta-lactamase, MRSA: methicillin-resistant *Staphylococcus aureus*, OR: odds ratio, SOFA: sequential organ failure assessment

###### 

Multivariate Analysis of Risk Factors Associated with ESBL *E. Coli* bacteremia.

  Risk factor                                    OR (95% CI)        p value
  ---------------------------------------------- ------------------ ---------
  Immunosuppressive drug or corticosteroid use   2.45 (1.01-5.96)   0.048
  Quinolones                                     3.70 (1.49-9.18)   0.005
  Third-generation cephalosporins                ND                 ND
  Anti-MRSA agents                               ND                 ND
  Carbapenems                                    ND                 ND
  Fourth-generation cephalosporins               ND                 ND
  Second-generation cephalosporins               ND                 ND
  Nosocomial infection                           ND                 ND
  Urinary catheter                               ND                 ND

CI: confidence interval, *E. coli*: *Escherichia coli*, EBSL: extended-spectrum beta-lactamase, MRSA: methicillin-resistant *Staphylococcus aureus*, ND: not detected, OR: odds ratio

Carbapenems group vs. tazobactam/piperacillin and cefmetazole group
-------------------------------------------------------------------

Of the 31 patients with ESBL *E. coli* bacteremia, nine (29.0%) received carbapenems, four (12.9%) received TAZ/PIPC, and two (6.5%) received CMZ consistently from the empirical therapy until the end of treatment. The univariate analyses of clinical characteristics and laboratory findings of patients with ESBL *E. coli* bacteremia treated with TAZ/PIPC, CMZ, or carbapenems are shown in [Table 5](#t005){ref-type="table"}. The patients\' background and mortality did not differ between the patients in the TAZ/PIPC or CMZ groups and the carbapenems group.

###### 

Clinical Characteristics and Laboratory Findings of ESBL *E. Coli* bacteremia Treated with Tazobactam/piperacillin or Cefmetazole or Carbapenem Consistently from Empirical Therapy until the End of Treatment.

  ------------------------------------------------------------------------------------------------------------------------------
  Variables                                      Tazobactam/Piperacillin or\   Carbapenem Group\   p value^a^             
                                                 Cefmetazole Group (n=6)       (n=9)                                      
  ---------------------------------------------- ----------------------------- ------------------- ------------ --------- ------
  Female gender                                  3                             (50%)               7            (77.8%)   0.33

  Age ≥ 70                                       4                             (66.7%)             1            (11.1%)   0.09

  Underlying disease                                                                                                      

  Malignancy                                     3                             (30%)               7            (77.8%)   0.33

  Immunosuppressive drug or corticosteroid use   2                             (33.3%)             4            (44.4%)   1.00

  Diabetes mellitus                              0                             (0%)                2            (22.2%)   0.49

  Cardiovascular disease                         0                             (0%)                2            (22.2%)   0.49

  Autoimmune disease                             0                             (0%)                1            (11.1%)   1.00

  Respiratory disease                            0                             (0%)                1            (11.1%)   1.00

  Digestive disease                              1                             (16.7%)             1            (11.1%)   1.00

  Endocrine disease                              1                             (16.7%)             0            (0%)      0.40

  Chronic renal failure                          1                             (16.7%)             2            (22.2%)   1.00

  Central nervous system disease                 1                             (16.7%)             1            (11.1%)   1.00

  Leukocyte count ≥ 12,000 (/μL)                 1                             (16.7%)             1            (11.1%)   1.00

  CRP ≥ 10 (mg/dL)                               2                             (33.3%)             4            (44.4%)   1.00

  SOFA score ≥ 5                                 4                             (66.7%)             3            (33.3%)   0.32

  Nosocomial infection                           5                             (83.3%)             6            (66.7%)   0.60

  Hospitalization within 90 days                 3                             (50%)               4            (44.4%)   1.00

  Urinary catheter                               1                             (16.7%)             4            (44.4%)   0.58

  Source of bacteremia                                                                                                    

  Urinary tract                                  3                             (50%)               3            (33.3%)   0.62

  Biliary tract                                  1                             (16.7%)             1            (11.1%)   1.00

  Mortality^b^                                   0                             (0%)                0            (0%)      1.00
  ------------------------------------------------------------------------------------------------------------------------------

^a^Fisher analysis.

^b^Both *E. coli* infection-related and otherwise.

CRP: C-reactive protein, *E. coli*: *Escherichia coli*, ESBL: extended-spectrum beta-lactamase, SOFA: sequential organ failure assessment

Discussion
==========

Our study showed the following results: First, the susceptibility rates of levofloxacin, gentamicin, and SMX/TMP against ESBL *E. coli* were significantly lower than those against non-ESBL *E. coli*. Second, the use of quinolones and immunosuppressive drugs or corticosteroids was an independent predictor of ESBL *E. coli* bacteremia. Third, the mortality did not differ between the patients with ESBL *E. coli* bacteremia and those with non-ESBL *E. coli* bacteremia. Fourth, regardless of the background and severity in patients with ESBL *E. coli* bacteremia, the mortality did not differ between the patients in the TAZ/PIPC or CMZ group and the carbapenems group.

In the past, the mechanisms of quinolone resistance in the *Enterobacteriaceae* were reported to be associated with a chromosomal mutation. However, in recent years, the resistant strains with plasmid-mediated quinolone resistance (PMQR) have been frequently reported ([@B21],[@B22]). It has thus become clear that plasmids with PMQR genes frequently hold ESBL genes at the same time ([@B23]). In addition, Souverein et al. reported that the genes encoding for the resistance of aminoglycosides are frequently found in the plasmids of ESBL-producing *Enterobacteriaceae* ([@B24]). Furthermore, sulphonamides and antifolate combinations almost certainly demonstrate the fact that ESBL-encoding plasmids often carry sulphonamides 1 (*sul1*) and *sul2* along with various dihydroflavonol 4-reductase genes, which compromise TMP ([@B25],[@B26]). Livermore et al. reported that *sul1* and *sul2* genes were associated with SMX MICs of \>1,024 mg/L compared with 1-128 mg/L for the gene-negative *E. coli* isolates ([@B27]). In addition, organisms with *sul1* or *sul2* genes together with SMX resistance determinants were resistant to SMX/TMP, with MICs generally of ≥128 mg/L. From the above, many of the ESBL-producing *Enterobacteriaceae* are thus considered to confer multidrug resistance against quinolones, aminoglycoside, and SMX/TMP.

Some studies reported the use of quinolones to be an independent predictor of ESBL *E. coli* bacteremia ([@B6],[@B7],[@B28],[@B29]). A previous report showed that quinolones will wield selection pressure on the intestinal flora that will favor ESBL *E. coli* proliferation and infection in susceptible patients ([@B30]). Further, a previous report showed a decline in the isolation rate of ESBL *E. coli* due to the reduction of fluoroquinolone usage ([@B31]). Therefore, with proper quinolone use, there is a potential to reduce the incidence of ESBL *E. coli* bacteremia.

Although previous studies indicate that there are various factors associated with ESBL bacteremia, the particular association with immunosuppressive drugs or corticosteroid use that we observed based on a multivariate analysis is an unusual finding. A previous report has shown that in mice, bacterial translocation from the intestinal tract was induced by immune deficiency due to immunosuppressive agents, even without any direct invasion into the intestinal tract ([@B32]). Furthermore, another report has shown that ESBL producing bacteria also frequently colonize the lower intestinal system, and therefore are a major source for ESBL distribution ([@B33]). These findings suggest that patients receiving immunosuppressive agents are at greater risk for ESBL producing bacteria acquisition and bacteremia. In the present study, although the existence of a relationship between ESBL *E. coli* bacteremia and use of immunosuppressive agents or steroids was suggested, we believe that more cases should be collected to confirm this relationship.

Some studies reported that the mortality was higher among patients in the ESBL-producing *Enterobacteriaceae* bacteremia group than in patients in the non-ESBL-producing *Enterobacteriaceae* bacteremia group ([@B1],[@B5],[@B7],[@B8]). One such study in a tertiary hospital showed that 30-day mortality of patients with bacteremia due to ESBL *E. coli* was significantly higher than for the patients in the non-ESBL *E. coli* control group (62.5% vs 12.5%, p=0.0091) ([@B7]). Moreover a study in Japan reported the SOFA score and 30-day mortality of patients with bacteremia due to Cefotaxime-non-susceptible *E. coli* or *Klebsiella pneumoniae* to be higher than that of patients with bacteremia due to cefotaxime-susceptible *E. coli* or *Klebsiella pneumoniae* (SOFA score: 5 vs 2, p\<0.001, 30-day mortality: 21% vs 5% p\<0.001) ([@B9]). In contrast, in the present study, the SOFA score and 30-day mortality did not differ between the patients in the ESBL *E. coli* bacteremia and non-ESBL *E. coli* bacteremia groups (SOFA score: 3.6 vs 3.8, 30-day mortality: 9.7% vs 9.2%). Further, in our study, the use of carbapenems or TAZ/PIPC, or CMZ as treatment for patients with ESBL *E. coli* bacteremia were relatively high among empirical and definitive therapy (58.1% and 90%, respectively). Therefore, we speculated that the mortality did not differ between the two groups because there was no significant difference in the underlying disease and SOFA scores among the two groups, and the use of appropriate empirical and definitive therapy for ESBL *E. coli* bacteremia was relatively high.

The current standard therapy for infections caused by ESBL-producing pathogens is a carbapenem ([@B3],[@B34]). A previous report at a tertiary hospital showed that the adjusted risk of death was 1.92 times higher for patients receiving TAZ/PIPC compared with carbapenem as empirical therapy ([@B35]). In contrast, it has recently been reported that β-lactam/β-lactamase inhibitors (BLBLI) including TAZ/PIPC ([@B36]) and cephamycins including CMZ ([@B37]) are suitable alternatives to carbapenems for treating patients with bacteremia caused by ESBL *E. coli*. Our study results show that the mortality rates of the patients with ESBL *E. coli* bacteremia treated with TAZ/PIPC or CMZ versus carbapenem were both 0%. These findings may suggest that TAZ/PIPC or CMZ are effective alternatives to carbapenem treatment for patients with ESBL *E. coli* bacteremia.

Our study is associated with several limitations. First, the only bacteria targeted in this study were *E. coli*. We will need to collect and analyze the number of patients with bacteremia caused by ESBL-producing organisms such as *Klebsiella* spp*. and Enterobacter* spp*.* in addition to *E. coli*. Second, as this study was conducted only with patients at a tertiary hospital, there is unavoidably some selection bias. We will need to collect and analyze the number of patients with bacteremia caused by ESBL-producing organisms in a community hospital setting in addition to a tertiary hospital. Third, we conducted a retrospective study in order to primarily investigate the risk factors of bacteremia caused by ESBL *E. coli*. We will need to carry out a prospective study, such as in the comparative study between carbapenems and other antibiotics against bacteremia caused by ESBL-producing organisms. Fourth, in [Table 5](#t005){ref-type="table"}, because of the small number of cases, the power of the statistical evaluation decreased. We will need to collect and analyze the number of patients with ESBL *E. coli* bacteremia treated with TAZ/PIPC or CMZ, or carbapenem.

In conclusion, our study showed that mortality did not differ between patients in the ESBL *E. coli* bacteremia and non-ESBL *E. coli* bacteremia groups. TAZ/PIPC or CMZ may therefore be an effective treatment modality for patients with ESBL *E. coli* bacteremia. The use of quinolones and immunosuppressive drugs or corticosteroids was suggested to be an independent predictor of ESBL *E. coli* bacteremia. Whenever we encountered patients with a history of receiving these drugs, it was necessary to perform antibiotic therapy with ESBL *E. coli* in mind. Furthermore, it is crucial to elucidate whether the proper use of quinolones has the potential to reduce the chance of patients developing ESBL *E. coli* bacteremia.
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